Publication Name	World Journal of Transplantation
Manuscript ID	6958
Country	Spain

Received	2013-11-06 17:06
Peer-Review Started	2013-11-08 19:46
To Make the First Decision	2013-12-13 13:37
Return for Revision	2013-12-17 16:24
Revised	2014-01-29 05:08
Second Decision	2014-02-19 11:19
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-02-19 11:42
Articles in Press	2014-05-23 13:20
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-03-17 14:25
Typeset the Manuscript	2014-06-30 10:26
Publish the Manuscript Online	2014-07-20 20:07

ISSN	2220-3230 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Autobiography
Article Title	Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients
Manuscript Source	Invited Manuscript
All Author List	Ainhoa Fernández-Yunquera, Cristina Ripoll, Rafael Bañares, Marta Puerto, Diego Rincón, Ismael Yepes, Vega Catalina and Magdalena Salcedo
Funding Agency and Grant Number	Funding Agency Grant Number Novartis Pharma Schweiz AG
Corresponding Author	Magdalena Salcedo, Chief Doctor, Department of Liver Transplantation, Hospital General Gregorio Mara?ón, C/ Doctor Esquerdo no 46, 28028 Madrid, Spain. magdalena.salcedo@salud.madrid.org
Key Words	Everolimus; Rapamycin; Liver fibrosis; Mammalian target of rapamycin; Transplantation
Core Tip	This study tries to approach the possible antifibrotic effect of everolimus, a mammalian target of a rapamycin inhibitor, in the clinical setting. Some studies in animal models suggest that it could also have an antifibrotic effect. The main conclusion of this study is that liver transplantation recipients with everolimus monotherapy had less serum expression of transforming growth factor-? and hyaluronic acid than matched patients with anti-calcineurins that play an important role in liver fibrosis. The study offers the rationale for much needed future randomized controlled trials that evaluate the modulation of post-transplant fibrosis.
Publish Date	2014-07-20 20:07
Citation	Fernández-Yunquera A, Ripoll C, Bañares R, Puerto M, Rincón D, Yepes I, Catalina V, Salcedo M. Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. World J Transplant 2014; 4(2): 133-140
URL	http://www.wjgnet.com/2220-3230/full/v4/i2/133.htm
DOI	http://dx.doi.org/10.5500/wjt.v4.i2.133

Full Article (PDF)	WJT-4-133.pdf
Full Article (Word)	WJT-4-133.doc
Manuscript File	6958-Review.doc
Answering Reviewers	6958-Answering reviewers.pdf
Copyright License Agreement	6958-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	6958-Language certificate.pdf
Peer-review Report	6958-Peer reviewer(s).pdf
Scientific Editor Work List	6958-Scientific editor work list.doc